Dysadherin: A Novel Oncogenic Molecular Biomarker in Oesophageal Cancer. Dysadherin is a well-described cancer-associated protein and a potential oncogenic molecular target with promising future significances. It signifies augmented tumorigenesis with enhanced metastatic potential and hematogenous spread and is thus linked.
Its main interaction in carcinogenesis takes place with E-cadherin; the most important adhesion molecules of the cadherin family. E-cadherin mediates homophilic cell-to-cell adhesion and promotes adherence between neighboring epithelial cells. Dysadherin and its closely related E-cadherin, has been studied in various cancers and its correlation with cancer While the role.
squamous cell carcinoma of all stages. On the contrary, studies based on human cancer cell lines have demonstrated that introduction of small interfering RNA against Dysadherin leads to downregulation and subsequent membranous under expression of Dysadherin, instigating accordingly decreased collective and individual cell motility with subsequent inhibition of tumour.
The correlation between immunohistochemically evaluated Dysadherin expression with patient clinicopathological data was studied. In the group of Oesophageal tumours expressing both Dysadherin and E-cadherin, prognosis was slightly better, but still poorer compared to the group of tumours that displayed no Dysadherin expression. Dysadherin plays a pivotal role in the carcinogenic process and can therefore become a target of novel oncological agents in an attempt to arrest disease progression and metastasis with obvious implications in prognosis and long-term survival.
Further research is needed in order to explore the role of this promising oncogenic molecular biomarker in Oesophageal carcinomas. Dysadherin plays a pivotal role in the carcinogenic process and can therefore become a target of novel oncological.
Cancer Stud Mol Med Open J. 2017; 3(2): e5-e6. doi: 10.17140/CSMMOJ-3-e005
